TMC 310911

Drug Profile

TMC 310911

Alternative Names: ASC-09; TMC-310911

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland
  • Class Antiretrovirals
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 01 Oct 2016 Tibotec Pharmaceuticals withdraws a phase I trial (PEPI-TiDP23-C104) in healthy volunteers prior to enrollment due to a strategic decision (NCT00908414)
  • 10 Aug 2015 No recent reports on development identified - Phase-I for HIV-1 infections (Combination therapy) in Ireland (PO)
  • 10 Aug 2015 No recent reports on development identified - Phase-II for HIV-1 infections (Monotherapy, Treatment-naive) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top